Akynzeo (netupitant) is a small molecule pharmaceutical. Netupitant was first approved as Akynzeo on 2014-10-10. It has been approved in Europe to treat nausea, neoplasms, and vomiting. It is known to target substance-P receptor. Akynzeo's patents are valid until 2035-09-25 (FDA).
|Indication||nausea, neoplasms, vomiting|
|Drug Class||Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists|